ABSTRACT
OBJECTIVE:To compare the effects of Qili qiangxin capsules and Compound danshen drop pills on related indexes of acute myocardial infarction(AMI)patients without reflow after percutaneous coronary intervention(PCI). METHODS:A total of 90 AMI patients without reflow after PCI were randomly divided into Compound danshen drop pills group (45 cases) and Qili qiangxin capsules group(45 case). Both groups were given Aspirin chewable tablets 300 mg and Clopidogrel sulfate tablets 300 mg before PCI. After surgery,both groups were given Aspirin chewable tablets 100 mg,once a day+simvastatin chewable tablets 10 mg,once a day. Based on it,Compound danshen drop pills group was given Compound danshen drop pills,10 pills,3 times a day. Qili qiangxin capsules group was given Qili qiangxin capsules,4 capsules,3 times a day. Both groups were treated for consec-utive 6 months. The blood flow classification of TIMI,LEVF,β1-AR,β2-AR,α1-AR,bleeding and the occurrence of major cardio-vascular events were observed in 2 groups before and after treatment. The occurrence of ADR was recorded. RESULTS:Bafore treatment,there was no statistical significance in the blood flow classification of TIMI,the levels of β1-AR,β2-AR and α1-AR be-tween 2 groups(P>0.05). After treatment,the case number of 0-2 degree blood flow classification of TIMI in 2 groups were signif-icantly lower than before treatment while the case number of 3 degree were significantly higer than before treatment;the levels ofβ1-AR,β2-AR and α1-AR were significantly lower than before treatment,while LEVF was significantly higher than before treatment;LEVF of Qili qiangxin capsules group was significantly higher than that of Compound danshen drop pills group,with statistical signifi-cance (P0.05). No obvious ADR was found in 2 groups during treatment. CONCLUSIONS:Qili qiangxin capsules is similar to Com-pound danshen drop pills in improving no-reflow efficacy and safety of AMI patients after PCI,but it is better than Compound dan-shen drop pill in improving cardiac function.